Empiric stereotactic body radiotherapy for presumed early-stage lung cancer
Empiric SBRT is a safe and effective treatment for presumed early-stage NSCLC in patients without histopathological confirmation. Even in patients requiring oxygen therapy and with severe comorbidities, long-term survival is feasible with acceptable treatment-related toxicity. Optimal dose fractionation and biologically effective dose (BED) levels for frail patients without histological confirmation remain undefined. Prospective trials are warranted to determine the most effective and safe SBRT regimens for this vulnerable patient population.
Authors
- Lukas Käsmann (ORCID: https://orcid.org/0000-0001-6260-5249)
- Chukwuka Eze (ORCID: https://orcid.org/0000-0003-3779-1398)
- Claus Belka (ORCID: https://orcid.org/0000-0002-1287-7825)
- Nina-Sophie Schmidt-Hegemann (ORCID: https://orcid.org/0000-0002-2091-3603)
- Cedric Richlitzki
- Amanda Tufman (ORCID: https://orcid.org/0000-0001-9243-9050)
- Sina Mansoorian
- Thomas Duell (ORCID: https://orcid.org/0000-0002-1039-2090)
- Esra Degerli
- Niels Reinmuth (ORCID: https://orcid.org/0000-0002-7369-4512)
- Farkhad Manapov
- Karim El-Marouk
- Diego Kauffmann‐Guerrero (ORCID: https://orcid.org/0000-0003-1471-3290)
- Khulangaa Khaltar
Institutions
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- LMU Klinikum (DE)
- Asklepios Fachkliniken München-Gauting (DE)
- German Center for Lung Research (DE)
- Ludwig-Maximilians-Universität München (DE)
- Fresenius Medical Care (Germany) (DE)
Publication Details
- Journal
- Strahlentherapie und Onkologie
- Published
- 2025-08-04
- DOI
- https://doi.org/10.1007/s00066-025-02434-8
- Citations
- 1
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52